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E-mail address: fpalm@farmbiol.uniba.it (F. PalmieTo date, 22 mitochondrial carrier subfamilies have been functionally identiﬁed based on substrate
speciﬁcity. Structural, functional and bioinformatics studies have pointed to the existence in the
mitochondrial carrier superfamily of a substrate-binding site in the internal carrier cavity, of two
salt-bridge networks or gates that close the cavity alternatively on the matrix or the cytosolic side
of the membrane, and of conserved prolines and glycines in the transmembrane a-helices. The sig-
niﬁcance of these properties in the structural changes occurring during the catalytic substrate trans-
location cycle are discussed within the context of a transport mechanism model. Most
experimentally produced and disease-causing missense mutations concern carrier regions corre-
sponding to the substrate-binding site, the two gates and the conserved prolines and glycines.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial carriers (MCs) are nuclear-coded membrane pro-
teins that transport a variety of solutes (di- and tricarboxylates,
keto acids, amino acids, nucleotides and coenzymes/cofactors)
across the inner mitochondrial membrane (see [1,2] for reviews).
Besides providing a link between mitochondrial and other cell
compartments, MCs play a role in regulating and maintaining a
balance between cytosol and mitochondrial matrix, for example,
of the phosphorylation and redox potentials. Some carriers, or
one of their isoforms if any, are widely distributed in all or nearly
all tissues, whereas others are tissue speciﬁc and their limited dis-
tribution reﬂects their importance in special tissues, e.g., for fatty
acid biosynthesis or thermogenesis.
MCs are small proteins normally possessing a molecular mass of
about 30–34 kDa. A main feature is the presence of three internal
repeated sequences [3] which were noted immediately after the
ﬁrst MC, the ADP/ATP carrier, had been sequenced [4]. This striking
pattern of repeats was also observed in the subsequent ﬁve MCschemical Societies. Published by E
soform 1; MC, mitochondrial
oglutarate/malate carrier; Pi,
r family
maco-Biologico, Università di
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ri).sequenced, leading to the important conclusion that MCs belong
to a single protein family, called the mitochondrial carrier family
(MCF). All MCF members of known function exhibit a tripartite
structure consisting of three tandemly repeated domains of about
100 amino acids in length. Each domain contains two hydrophobic
stretches separated by extensive hydrophilic regions and a signa-
ture sequence motif PX[D/E]XX[K/R]X[K/R] (20–30 residues) [D/
E]GXXXX[W/Y/F][K/R]G. Unlike the other members of the family,
two subfamilies, the aspartate/glutamate and ATP-Mg/Pi carriers
that share Ca2+-binding properties, have a peculiar structure con-
sisting of two domains: a C-terminal domain or catalytic portion,
which contains all the features of the MCF described above, and
an N-terminal extensive domain or regulatory portion (more than
150 amino acids), which contains three or four EF-hand Ca2+-bind-
ing motifs. The substrates transported by MCs markedly vary not
only in nature (anions, cations or zwitterions) and structure but
also in size, from the smallest, H+, to the largest and most highly
charged species transported through membranes, e.g., NAD+, FAD
and coenzyme A. Moreover, the majority of MCs catalyze an oblig-
atory 1:1 substrate exchange reaction. Only a few mediate unidi-
rectional transport of substrates, such as carnitine, H+-
compensated phosphate or H+-compensated glutamate, besides
exchange.
This review highlights recent information and new insights
about the structure and function of MCs. These novel concepts in
the ﬁeld of MCs, and in particular the role of the conserved prolineslsevier B.V. All rights reserved.
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tional changes occurring during the catalytic transport cycle, have
been discussed within the context of a proposed mechanismmodel
by which MCs operate.2. Extension of the MCF
Until 1997, only six MCs were sequenced, after their puriﬁca-
tion from mitochondria, by Edman degradation or by molecular
biology techniques based on minimal protein sequence informa-
tion. They are the ADP/ATP carrier, the uncoupling protein and
the carriers for phosphate (Pi), citrate, oxoglutarate/malate and
carnitine/acylcarnitines (see [5] and references therein). In the
post-genomic era, searching genome databases using the sequence
features of the MCF has revealed a large number of family mem-
bers. The genome of Saccharomyces cerevisiae encodes 35 MCs, that
of Arabidopsis thaliana 58 and the human genome about 50. Actu-
ally, in man the MCF, named the human mitochondrial solute car-
rier family (SLC25), is by far the largest of the known solute carrier
(SLC) families.
The ﬁrst step in elucidating carrier function is to discover the
substrate(s) transported by a particular carrier. One of the most
effective methods to identify substrate speciﬁcity of new MCs con-
sists of gene expression in Escherichia coli and/or S. cerevisiae, puri-
ﬁcation of the gene products and their reconstitution into
liposomes in which substrate transport is assayed by direct mea-
surements. By employing this strategy, numerous MCs have been
identiﬁed at the molecular and biochemical level mainly in yeast,
plants and humans (see [2,6–13] and references therein). Phyloge-
netic clustering, genetic information, knowledge of cell metabo-
lism and complementation of phenotypes have often provided
clues to the choice of substrate to be tested; yet, these data are
not conclusive and substrate speciﬁcity remains to be determined
by transport assays.
Based on their substrate speciﬁcity, MCs can be divided into
subfamilies. Until now, the following subfamilies have been
identiﬁed: uncoupler protein, and the carriers for ADP/ATP, Pi,
2-oxoglutarate/malate, citrate/malate, carnitine/acylcarnitines,
dicarboxylates (malate/Pi), ornithine and other basic amino acids,
succinate/fumarate, oxaloacetate/sulfate, oxodicarboxylates, ade-
nine nucleotides in peroxisomes, aspartate/glutamate, glutamate,
thiamine pyrophosphate and deoxynucleotides, S-adenosylmethi-
onine, GTP/GDP, ATP-Mg/Pi, pyrimidine nucleotides, NAD+, coen-
zyme A/adenosine 30,50-diphosphate, and FAD and folate (see
[2,6,7] for reviews; [8–19]). Therefore, a total of 22 transport func-
tions have been disclosed. Often, different subfamilies exhibit an
overlapping of transported substrates, which also sometimes oc-
curs for the deﬁning substrates of each subfamily reported above.
It is worth mentioning that the best substrate translocated in
reconstituted liposomes might not be the most important sub-
strate under physiological and pathological conditions and even
in different tissues or specialized cells. Furthermore, some carriers
may transport additional yet untested substrates, as has recently
been found for a-isopropylmalate as substrate of the yeast oxalo-
acetate/sulfate carrier, Oac1p [20]. In addition, most of the subfam-
ilies reported above are present in all eukaryotes. However, a few
subfamilies are more speciﬁc. For example, orthologs of the yeast
GTP/GDP carrier are not present in mammals or plants [21] and
therefore this carrier is a good target for novel drugs effective
against pathogenic fungi and/or protista of Homo sapiens (e.g., Can-
dida albicans and Leishmania chagasi) and plants (e.g., Gibberella
zeae).
Further important steps in unravelling the physiological role of
MCs are: their subcellular localization (as some MCF members
were found in non-mitochondrial organelles, such as peroxisomesand chloroplasts ([13] and references therein)); tissue distribution;
kinetic parameters; metabolite distribution in different cell com-
partments; and phenotype analysis of organisms or cell lines in
which a particular carrier gene had been knocked out/knocked
down or overexpressed. This analysis has been commonly per-
formed in yeast and to a lesser degree in both plants and animals.3. Structure
According to the tripartite structure and hydrophobic proﬁles of
the ﬁrst sequenced carriers, it was suggested that each of the three
repeats that make up MCs is folded into two membrane-spanning
a-helices forming a structure with a total of six a-helices ([3,5] and
references therein). This two-dimensional model of MCs was con-
ﬁrmed by topological data based on the accessibility of carriers to
peptide-speciﬁc antibodies, proteolytic enzymes and other imper-
meable reagents. These data also proved that the N- and C-termini
are exposed to the cytosolic side of the membrane, the loops con-
necting the two a-helices of each repeat are located on the matrix
side, and the two shorter segments connecting the three repeats
are on the cytosolic side (see [22] for a review and references
therein; [23]).
In 2003, the 3D structure of a member of the MCF, the ADP/ATP
carrier in complex with its inhibitor, carboxyatractyloside, was
determined [24]. This structure consists of a six-transmembrane
a-helix (H1–H6) bundle and three short a-helices (h12, h34 and
h56) parallel to the membrane plane on the matrix side. The
six transmembrane a-helices, in order from 1 to 6, line a funnel-
shaped cavity open towards the cytosol in a counter-clockwise
fashion. In each repeated domain, the ﬁrst part of the signature
motif, PX[D/E]XX[R/K], is located at the C-terminus of the odd-
numbered transmembrane a-helices, whereas the second part,
[D/E]GXXXX[W/Y/F][R/K]G, is located at the N-terminus of the
even-numbered transmembrane a-helices. The prolines of the sig-
nature motif PX[D/E]XX[R/K] sharply kink the odd-numbered
transmembrane a-helices, and the charged residues of the three
signature motifs form a salt-bridge network that closes the cavity
(occupied by the inhibitor) on the matrix side. Among the possible
considerations to be made about this crystal structure the follow-
ing are worth mentioning: it should roughly correspond to the ‘‘c”
(cytosolic)-state of the ADP/ATP carrier, as carboxyatractyloside is
an inhibitor that blocks the carrier in this state; it exhibits a 3-fold
pseudo-symmetry in line with the 3-fold sequence repeats, as also
observed by electron microscopy of the yeast ADP/ATP carrier 2D
crystals [25]; and, based on the strikingly conserved primary struc-
ture, it most likely represents the common folding of all the other
MCF members and has therefore been used as a template for build-
ing homology models of various carriers. Furthermore, the ion pair
network mentioned above constitutes the gate of MCs on the ma-
trix side.4. Findings based on sequence alignment analysis
Knowledge of substrate speciﬁcity of MCF members and the
identiﬁcation of subfamilies have been employed to analyze multi-
ple sequence alignments of MCs on three different levels: complete
sequences, sequences of the three repeats and sequences of the
transmembrane a-helices. Indeed, aside from the pioneering ﬁnd-
ings in 1982 of Saraste and Walker [3], remarkable and useful
information has recently been obtained with this kind of analysis.
By considering the amino acids conserved in alignments of carriers
with known substrate speciﬁcity and using comparative models of
these carriers, Robinson and Kunji [26] proposed a ‘‘common sub-
strate-binding site” for MCs, i.e. a similarly located substrate
binding site. This site is formed by the residues of the three
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cavity of the carrier at the midpoint of the membrane one-and-a-
half helix turns above the matrix salt-bridge network that closes
the bottom of the cavity. Among the proposed three contact points,
point II on helix 4 is the most important because it alone can dis-
criminate between amino acids, carboxylic acids (including keto
acids) and nucleotides. In fact, point II is represented by R[D/E]
in amino acid carriers, by R[QHNTAV] in carboxylic acid carriers
and G[IVLMT] in nucleotide carriers. There are, however, some
exceptions; for example, point II of ornithine carrier isoform 2
(ORC2) is QE and contact points II of Pi carrier and GTP/GDP carrier
are [R/K]Q and RN, respectively, which are characteristic of carriers
for carboxylic acids. Recent evidence indicates that the residues of
the odd-numbered transmembrane a-helices protruding into the
cavity at the level of contact points I, II and III may also participate
in substrate binding. In fact, the substrate of the yeast oxaloacetate
carrier (Oac1p), a-isopropylmalate, interacts with the side-chain of
V37, which is the residue of the ﬁrst transmembrane a-helix (pro-
truding into the cavity) at the height of the substrate-binding site
[20]. Furthermore, some mutations of odd helix residues at the
height of contact points (e.g., G133, A134 and S237 of the oxoglu-
tarate carrier and H32 of the Pi carrier) inhibit transport activity
[27,28].
Analysis of inter-repeat multiple sequence alignment of MCs of
known function (substrate speciﬁcity) revealed triplets (formed
by the aligned residues of each carrier), which may be either sym-
metrical, consisting of three identical amino acids, or asymmetrical,
consisting of different amino acids [29]. Highly symmetrical and
conserved triplets are important for structure and/or transport
mechanism, whereas asymmetrical triplets for recognition and/or
binding of the substrate (which usually has an asymmetrical distri-
bution of functional groups). Based on the 3D structure of the ADP/
ATP carrier, Fig. 1 shows the triplets of residues protruding into the
cavity of S. cerevisiae, human and some A. thaliana carriers. These
residues belong to the even-numbered (triplets 73–96) and odd-
numbered (triplets 11–34) transmembrane a-helices of the above
carriers. The P (triplet 28) of the odd helices, and the G (triplet 73)
and P (triplet 83) of the even helices are also shown in Fig. 1, though
they do not protrude into the cavity. Typical asymmetrical triplets
(80 and 81) correspond to the two amino acids which are located
at contact points I, II and III. Typical symmetrical triplets (30 and
33) concern the positively and negatively charged residues involved
in the matrix salt-bridge network [24] (formed by the charged res-
idues of the sequence motif PX[D/E]XX[K/R]). Other symmetrical
triplets, though less conserved (triplets 93 and 96), are localized
at the C-terminus of the even-numbered transmembrane a-helices
and have been proposed to form a salt-bridge network on the cyto-
solic side (formed by the charged residues of the motif [F/Y][D/
E]XX[R/K]) [29]. This ion pair network would close the carrier in
the ‘‘m” (matrix)-state [29] and therefore constitute the gate of
MCs on the cytosolic side. By considering the triplets of Fig. 1 in light
of substrate speciﬁcity, it is apparent that MC subfamilies are char-
acterized by speciﬁc triplets protruding into the carrier cavity. For
example, the ATP-Mg/Pi carrier subfamily is characterized by trip-
lets 84 (EYA) and 88 (KDS) and the thiamine pyrophosphate carrier
subfamily by triplets 23 (R[T/S]K), 34 (IT[K/R]) and 85 (GAT). These
triplets can therefore be used to predict the function (substrate
speciﬁcity) of yet unidentiﬁed carriers. Nevertheless, (i) some of
the characterizing triplets are shared by more than one subfamily,
as for example triplet 19 in the NAD+, FAD and pyrimidine nucleo-
tide carrier subfamilies, and triplets 22 and 85 in the glutamate
and aspartate/glutamate carrier subfamilies, and (ii) various sub-
families are characterized by more than three triplets.
The inter-helix multiple sequence alignment of Fig. 2 (top pa-
nel) highlights (i) in the odd transmembrane helices the presence
of a well-conserved glycine (orange arrow) nine residues beforethe prolines (grey arrow) of the PX[D/E]XX[K/R]X[K/R] sequence
motif, and (ii) in the even transmembrane helices the presence of
a conserved proline (grey arrow) 10 residues after the glycine (or-
ange arrow) corresponding to the last residue of the second part
([D/E]GXXXX[W/Y/F][R/K]G) of the sequence motif. It is interesting
that the above-mentioned G and P of the odd helices are aligned
with the G and P of the even helices (Fig. 2, top panel), reﬂecting
an antiparallel arrangement of odd and even helices (Fig. 2, bottom
panel). The P of the odd helices and the G of the even helices are
located about one-and-a-half helix turns below the substrate-bind-
ing site, and the G of the odd helices and the P of the even helices
about one helix turn above the substrate-binding site. Further-
more, the P of the odd helices are one-half helix turn above the ma-
trix ion pair network or matrix gate, whereas the P of the even
helices are two-and-a-half helix turns below the cytosolic ion pair
network or cytosolic gate.
As proposed for the P of the odd helices [24], we hypothesize
that the G of the odd helices and the G and P of the even helices
can also act as hinges to open or close the carrier on the matrix
or cytosolic side (see Section 6). It should also be noted that other
rather conserved G are present in small regions immediately pre-
ceding the above-mentioned G in both the odd and even trans-
membrane helices (orange boxes in Fig. 2, top panel). The G of
these regions may also participate in the hinge function of the
highly conserved G. Moreover, in some carriers the P of the even
helices are substituted by S, T and G (that can play a hinge role sim-
ilar to that of P especially when other S, T or G are near in the se-
quence [30]) and less frequently by hydrophobic residues (which
are known to be involved in helix formation and stabilization). In
the latter case, however, we have noted that MCs usually display
an incomplete cytosolic network. Interestingly, this is also true
when P of the odd helices are rarely substituted with hydrophobic
residues (e.g., in yeast dicarboxylate carrier [Dic1p], yeast suppres-
sor of Hm mutant [Yhm2p] and SLC25A46).5. Structure–function studies: the use of mutant proteins
The results of site-directed mutagenesis of the oxoglutarate car-
rier (OGC) and many other MCs [27,31–40] as well as the naturally
occurring mutations of MCs found in patients (see [41] for a re-
view), interpreted in the context of comparative models based on
the 3D structure of the ADP/ATP carrier, can be summarized as
follows:
(1) With a few exceptions, residues that interact with the lipid
bilayer tolerate replacement with cysteine.
(2) Few residues that participate in inter-helical interactions
signiﬁcantly inhibit transport activity when substituted.
These residues may play a role in stabilizing the a-helical
bundle while the carriers undergo conformational changes.
(3) Many residue replacements with cysteine located in the cav-
ity of the carrier (or their subsequent modiﬁcation by sul-
phydryl reagents) affect transport activity. In the case of
OGC, among the 60 residues protruding into the cavity, 37
displayed signiﬁcant transport inhibition when mutated to
cysteine and 21 total inhibition (65%) as compared to the
activity of C-less OGC. Critical for function are the charged
residues at the bottom of the cavity, which belong to the sig-
nature motif PX[D/E]XX[K/R]. Also important for function
are the residues of the even- and odd-numbered transmem-
brane a-helices protruding into the cavity at the height of
the substrate-binding site, because their substitution can
interfere with binding. There are other residues protruding
into the cavity that cannot be mutated into cysteine or mod-
iﬁed by sulphydryl reagents without a signiﬁcant loss in
Fig. 1. Alignment of amino acid triplets of 46 mitochondrial carriers (MCs) of Homo sapiens, 35 of Saccharomyces cerevisiae and some of their homologs in Arabidopsis thaliana.
Each triplet is formed by the three aligned residues of each carrier, which are derived from the inter-repeat multiple sequence alignment of the MCs indicated above. The
triplets are ordered horizontally according to the number of the ﬁrst-repeat amino acids of the bovine ADP/ATP carrier sequence (NP_777083). The carriers are listed
according to the following major groups of substrates: nucleotides; carboxylic acids including keto acids; amino acids; and other substrates. Amino acids are coloured
according to the default Jalview–Zappo style.
1934 F. Palmieri, C.L. Pierri / FEBS Letters 584 (2010) 1931–1939transport activity. These residues, located one, three and
particularly two helix turns above the substrate-binding site
and usually belonging more to the even than to the odd heli-
ces (according to available data), may also play a role in sub-
strate recognition or binding.(4) Also the importance of P and G helix residues is substantiated
by site-directed mutagenesis. Thus, odd helix residues G32,
G130, G230, P41, P139 and P239 aswell as evenhelix residues
G83, G87 and G183 (but not G281) mutated into cysteine
severely affect OGC transport activity. In OGC the residues
Fig. 2. Prolines and glycines in the even and odd transmembrane a-helices of MCs. Panel A: Inter-helix sequence alignment of selected MCs (AAC1, bovine ADP/ATP carrier
isoform 1; CoA, human coenzyme A/adenosine 30 ,50-diphosphate transporter; CAC, human carnitine/acylcarnitine carrier; Sfc1p, yeast succinate/fumarate carrier). Amino
acids are coloured according to the default Bioedit style. Orange arrows indicate the conserved Gly in odd- and even-numbered helices; orange boxes highlight the Gly-rich
regions in odd- and even-numbered helices; black arrows and boxes, the residues of the even and odd helices at the height of the common substrate-binding site; grey arrows
and boxes, the conserved Pro in odd and even helices; and red boxes, the matrix and cytosolic salt-bridge networks. Panel B: Lateral view of the 3D structure of the ADP/ATP
carrier (carboxyatractyloside not shown). The vertical triplet PPP of the odd helices (Panel A, top grey arrow) and the vertical triplet PIG of the even helices (Panel A, bottom
grey arrow) are in red and in surf representation; the vertical triplet GGG of the even helices (Panel A, bottom orange arrow) and the vertical triplet AGT of the odd helices
(Panel A, top orange arrow) are in yellow and in surf representation. Panel C: transmembrane a-helices H2 and H3 taken from the crystal structure of the ADP/ATP carrier. H2
and H3 are depicted to show the position of a P (red) and a G (yellow) in each as well as helix curvature. The H2H3 helices were selected because they do not overlap.
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servedG of the even helices, are T93, V193 and P291. Replace-
ments of these residues with cysteine do not signiﬁcantly
inhibit activity. However, the OGC mutants of the adjacent
residues Y94C and T293C exhibit transport of 65%.
6. Mechanism of transport
It is generally accepted that during the catalytic substrate trans-
location cycle, the carrier undergoes a reversible conformationalchange between the c-state and the m-state. In the ﬁrst case, the
substrate-binding site is exposed toward the cytosol and, in the
second, toward the mitochondrial matrix. The principal idea of this
hypothesis is the presence of a single carrier-binding site (in the
cavity) which is open alternatively to the two opposite sides of
the membrane. According to this mechanism, named ‘‘single bind-
ing center-gating pore mechanism” [42], the binding of the sub-
strate on one side induces structural changes in the carrier
reorienting the binding site to the opposite side. The substrate
now leaves the transport site allowing another substrate to be
bound and transported in the opposite direction. This mechanism
1936 F. Palmieri, C.L. Pierri / FEBS Letters 584 (2010) 1931–1939was ﬁrst suggested for the ADP/ATP carrier because of the exis-
tence of high-afﬁnity inhibitor ligands that bind to the carrier
either on the cytosolic side (atractyloside) or on the matrix side
(bongkrekate). These ligands remove ADP or ATP and their binding
is mutually exclusive, indicating a single reorienting binding site.
The existence of a c-state has been demonstrated by the crystal
structure of the carboxyatractyloside-ADP/ATP carrier complex
[24]. In addition, the reorientation of the binding site is supported
by the ‘‘common substrate binding site” [26] and by the kinetic
‘‘ping-pong mechanism” of carnitine/acylcarnitine carrier-cata-
lyzed transport [43]. Unfortunately, a 3D structure of MCs in the
m-state is not yet available. Moreover, the structural changes
occurring during the reversible transition between the c- and m-
states are unknown.
As an early event in substrate translocation through the carrier
protein an uncharacterized substrate recognition may occur.
Molecular dynamics studies indicate that a tyrosine ladder is
important for sliding the ADP to the binding site [44,45], as origi-
nally suggested by Pebay-Peyroula et al. [24]. According to the ‘‘in-
duced transition ﬁt” theory [46,47], substrate binding in the cavity
induces a rearrangement of the carrier in the transmembrane re-
gion to attain an optimum ﬁt between the protein and the sub-
strate corresponding to the transition state. Indeed, the carrier
substrate-binding site is composed of all carrier cavity residues
interacting with the substrate when the transition state is reached.
It is proposed that in the transition state the carrier is nearly closed
on both sides of the membrane and the substrate is bound at the
center of the carrier (Fig. 3). In particular, the substrate interacts
with the even and odd transmembrane helix residues of the simi-
larly located binding site as well as with other residues protruding
into the cavity above and below, depending on its size and shape.
The total binding energy of the protein–substrate interactions in
the transition state triggers additional structural changes which
are necessary to complete the catalytic cycle, including the open-
ing of the matrix or cytosolic gate (salt-bridge network) and the
closure of the other gate on the opposite side of the membrane.
We propose a model illustrating the conformational changes in-
volved in the transition between the two states based on current
knowledge as well as the role of P and G of the transmembrane
a-helices discussed above. When the substrate enters the carrier
in the c-state (see upper left truncated pyramid of Fig. 3A), as a re-
sult of the protein–substrate interaction helix 1 (deﬁned by seg-
ment P1–G1) tilts towards helix 5 (P5–G5), helix 5 towards helix 3
(P3–G3) and helix 3 towards helix 1 (see arrows at the vertices of
the yellow triangles of upper left truncated pyramid and top prism
of Fig. 3A). The same occurs for even helices 2, 4 and 6 (see arrows
at the vertices of the red triangles). When the substrate enters the
carrier in the m-state (see lower right truncated pyramid of
Fig. 3A), exactly the contrary occurs to complete the catalytic cycle
(see arrows at the vertices of the red and yellow triangles of lower
right truncated pyramid and bottom prism of Fig. 3A). For each
transmembrane a-helix, the tilt involves the entire helical segment
including the termini above and below the P and G, which are not
shown in Fig. 3A but are depicted in Fig. 3C. Looking at the carrier
from the cytosol, even and odd helices would be seen moving
clockwise during the c- to m-state transition, counter-clockwise
during the m- to c-state transition, and vice versa looking at the
carrier from the matrix side. Once the tilt is initiated by substrate
binding to the c-state, a swivel of the P in the even helices occurs
toward the cavity axis bringing together the [F/Y][D/E]XX[K/R]
portions whose charged residues form the cytosolic salt-bridge
network [29] and simultaneously the G in the odd helices act as
hinges rotating their N-termini (towards the cavity axis) behind
the cytosolic network (Fig. 3C, right side, upper segments). Con-
versely, after the tilt is induced by substrate binding to the m-state,
the kink at the P in the odd helices reorients the PX[D/E]XX[K/R]segments to form the matrix salt-bridge network, and a swivel of
the G in even helices rotates their N-termini (towards the cavity
axis) behind the matrix network (Fig. 3C, left side, lower
segments), as seen in the crystal structure of the carboxyatractylo-
side-ADP/ATP carrier complex [24]. The 3D structure of the ﬁrst
repeat is shown in Fig. 3B for direct comparison with the schematic
representation of a single repeat c-state depicted in Fig. 3C, left
side. As a result of these structural changes, in the transition from
the c- to the m-state, the gate on the matrix side breaks and the
even–odd helices move apart while they come together to close
the gate on the cytosolic side. The opposite occurs during the tran-
sition from the m- to the c-state. The model described above con-
cerns the mechanism of MC-catalyzed substrate exchange. In the
1:1 exchange, the activation energy barrier for the reorientation
of the substrate-binding site in the carrier is overcome only when
the substrate is bound to the protein. For some carriers, which cat-
alyze uniport (although at a lower rate) besides exchange, the acti-
vation energy barrier required for the conformational changes
leading to the transition between the two states is much lower
than that of obligatory exchange carriers [43,46]; thus, uniport car-
riers can reorient themselves in the absence of substrate. Accord-
ing to Robinson et al. [29], uniport mode of transport is related
to the weakness of one or both salt-bridge networks. An additional
consideration is that the above-described model implies that each
MC monomer possesses an internal translocation channel or path-
way. This means that MCs function as monomers, as strongly sug-
gested by negative dominance studies conducted with the yeast
ADP/ATP carrier [48].7. Diseases
In the last decade, the completion of human nuclear gene
sequencing and the ongoing identiﬁcation of MC gene function en-
abled the discovery of numerous diseases associated to defective
carriers (see [41] for a review and references therein). These disor-
ders are caused by alterations of the genes encoding MCs, which
are essential for either oxidative phosphorylation (e.g., the ADP/
ATP and the Pi carriers) or other metabolic pathways and cell
functions (e.g., the carriers for glutamate, aspartate/glutamate, thi-
amine pyrophosphate and carnitine/acylcarnitines). Their symp-
tomatology depends on the speciﬁc metabolism affected and its
relevance in speciﬁc tissues. To date, eleven MC-related diseases
have been well characterized biochemically and genetically. With
the exception of autosomal dominant progressive external oph-
thalmoplegia, all the other disorders are inherited in an autosomal
recessive manner. The ﬁrst nine diseases have been reviewed in
2008 [41]. Since then, two additional diseases, aspartate/glutamate
carrier isoform 1 (AGC1) deﬁciency and congenital sideroblastic
anemia, have been found.
AGC1 deﬁciency has been described in a child who presented
with severe hypotonia, psychomotor developmental arrest and sei-
zures beginning at a fewmonths of age, followed later by spasticity
[49]. At 8 months of age onward, magnetic resonance imaging of
the brain revealed lack of myelination in the cerebral hemispheres,
and proton magnetic resonance spectroscopy of the occipital and
frontal lobes showed a drastically reduced peak of N-acetyl aspar-
tate. The same traits were observed in knock-out mice for AGC1
[50]. Sequencing the patient’s SLC25A12 gene revealed a homozy-
gous c.1769A? G transition in exon 17, which produces a gluta-
mine-to-arginine substitution at position 590 of AGC1 [49]. This
mutation alters a highly conserved residue in the aspartate/gluta-
mate MC subfamily, which protrudes into the internal cavity of
the transporter just above the substrate-binding site and is delete-
rious for protein function. Indeed, recombinant mutant Q590R
AGC1 reconstituted into liposomes was completely unable to cata-
Fig. 3. Schematic representation of conformational changes of the six MC transmembrane a-helices occurring during the catalytic transport cycle. Panel A: Scheme showing
the structural changes limited to the transmembrane helix segments between P and G. In this panel, the changes have purposely been exaggerated to aid the reader. This
representation is intended mainly to emphasize the geometric perspective and, secondarily, to describe the transport mechanism. Truncated pyramids (left side) depict the c-
state after the release (bottom) and immediately after the entry of the substrate (top); prisms indicate the transition states, and truncated pyramids on the right the m-state
after the release (top) and immediately after the entry of the substrate (bottom). Substrate entering on the cytosolic side (green oval); substrate entering on the matrix side
(blue rectangle). The six transmembrane a-helices are designated by the segments that join the sides of prisms and truncated pyramids. The positions of the P and G of the
even and odd helices are denoted by the vertices at the top and bottom bases of the geometric solids. In the bottom bases, the P of the odd-numbered helices are located at the
vertices of the red triangles and the G of the even-numbered helices at the vertices of the yellow triangles. In the top bases, the P of the even helices are located at the vertices
of the red triangles and the G of the odd helices at the vertices of the yellow triangles. The arrows along the sides of the triangles indicate tilt direction of the transmembrane
helices. Panel B: Crystal structure of the bovine ADP/ATP carrier ﬁrst repeat, taken from the published 3D structure of the carboxyatractyloside-ADP/ATP carrier complex. The
conserved P and G positions in most MC odd and even transmembrane a-helices (see Figs. 1 and 2A) are indicated by G1, P1, G2 and P2. In the ADP/ATP carrier A19 is present
instead of G. A19 (G1) and G73 (G2) are shown in yellow and in surf representation; P28 (P1) and P83 (P2) in red and surf representation. Panel C: Scheme showing the
structural changes of the transmembrane a-helices of a single repeat (including the segments external to the P and G residues, which are those that undergo major changes).
For sake of clarity, the subscripts 1 and 2 were added to the P and G to more easily identify the odd- and even-numbered transmembrane helix. The left side corresponds to
the c-state, the right side to the m-state and the middle part to the transition state; the grey oval in the transition state denotes the bound substrate; the yellow arrows denote
the ability of G to bend the helices; and the red arrows indicate kink/swivel at the P. The angle of observation is the same as that of panel B. The carrier matrix axis is closer to
the reader.
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was proposed that arginine in position 590 traps the substrate at
the binding site impeding its movement through the protein andinteraction with the charged residues of the matrix gate [49].
AGC1 has two important functions: the ﬁrst is to supply aspartate
to the cytosol by catalyzing an exchange between intramitochon-
1938 F. Palmieri, C.L. Pierri / FEBS Letters 584 (2010) 1931–1939drial aspartate and cytosolic glutamate [51], and the second is to
participate in the transfer of reducing equivalents of NADH from
cytosol to mitochondria being a key component of the malate-
aspartate shuttle. Given that AGC1 is the only isoform of this car-
rier expressed in neurons, most symptoms of AGC1 deﬁciency
are due to lack of AGC1 function in neurons. In brain, the aspartate
exported from neuronal mitochondria is mainly utilized for the
production of N-acetyl aspartate which, in healthy individuals, is
the precursor of myelin lipids. Therefore, extensive and severe
hypomyelination, the dominant feature of this syndrome, is caused
by defective AGC1 in neurons. The symptomatology of AGC1 deﬁ-
ciency, on the other hand, suggests that the malate-aspartate shut-
tle is not so bioenergetically essential in neurons as generally
thought, probably because the alternative pathway of reducing
equivalent transfer into mitochondria, the glycerol-3-phosphate
cycle, is sufﬁciently active in neurons. In AGC1 deﬁciency, impaired
oxidative phosphorylation was ruled out based on the observations
that lactate accumulation was minor or absent and no focal lesions
in the basal ganglia and brainstem nuclei were revealed on mag-
netic resonance imaging. Moreover, mitochondrial ATP production
was drastically reduced after incubation of the patient’s muscle
mitochondria with glutamate plus malate, but not with any other
respiratory substrate tested [49].
Another error of metabolism is congenital sideroblastic anemia,
which is caused by defects in the SLC25A38 gene [52]. As indicated
by its name, this disease is characterized by severe anemia with
hypochromia, microcytosis and ringed sideroblasts in the bone
marrow (abnormal normoblasts with iron overload in the mito-
chondria). Patients are non-syndromic and present no develop-
mental anomalies. Until now, 11 SLC25A38 alterations, including
four missense mutations, have been found in patients in which
X-linked ALAS-2 (d-aminolevulinic acid synthase-2) gene muta-
tions were excluded [52]. In fact, ALAS-2, encoding erythroid-spe-
ciﬁc and intramitochondrially localized d-aminolevulinic acid
synthase, is the only known gene, besides SLC25A38, to cause
non-syndromic congenital sideroblastic anemia. The SLC25A38
gene is expressed in high amounts exclusively in erythroid cells,
as ALAS-2, and encodes a yet uncharacterized MCF member thatFig. 4. MC structural areas in which many disease-causing missense mutations are
located. The 3D crystal structure of the carboxyatractyloside-ADP/ATP carrier
complex (devoid of the inhibitor) is shown with the following regions in colour:
cytosolic gate (blue); substrate-binding site (orange); and matrix gate (purple). In
P–G level 1 and P–G level 2, prolines are shown in red and glycines in yellow.here we call SLC25A38p. To elucidate the pathogenesis of altered
SLC25A38-linked congenital sideroblastic anemia, elegant studies
were conducted in zebraﬁsh and S. cerevisiae demonstrating that
SLC25A38p plays a role in heme biosynthesis [52]. This conclusion
was based on the following observations: (i) silencing of the two
zebraﬁsh SLC25A38p homologs resulted in anemic embryos,
although the anemia was not as severe as that caused by ALAS-2
silencing; and (ii) S. cerevisiae cells lacking the yeast homolog of
SLC25A38p did not grow on the non-fermentable carbon source
glycerol, were unable to reduce sodium nitroprusside (which re-
quires heme-dependent cell-surface ferrireductase) and exhibited
a markedly decreased amount of cellular d-aminolevulinic acid.
Moreover, the SLC25A38-associated phenotype was similar to that
caused by ALAS-2 mutations. In addition, the presence of an argi-
nine-aspartate dipeptide in contact point II of SLC25A38p sug-
gested that this protein is a carrier for amino acids. On this basis,
it was hypothesized that SLC25A38p either imports glycine into
mitochondria or exchanges cytosolic glycine for mitochondrial d-
aminolevulinic acid across the mitochondrial membrane [52], i.e.
transports one of the substrates and the product of the ﬁrst step
in heme biosynthesis catalyzed by ALAS-2, thus explaining the
main feature of the disease, i.e. impaired heme production in ery-
throid cells.
Interestingly, among the 48 missense mutations found so far in
patients affected by diseases associated to MCs (see [41] for a re-
view; [49,52]), 30 concern residues that protrude into the internal
carrier cavity. These 30 mutations are located in the following re-
gions (Fig. 4): matrix gate (7); substrate-binding site (10); P-G level
1 (8); P-G level 2 (2); and cytosolic gate (3).8. Conclusions
In recent years, signiﬁcant progress has been made in character-
izing MCs functionally and structurally. By utilizing a unique and
powerful inhibitor, a breakthrough in the ﬁeld occurred in 2003
when the 3D structure of the carboxyatractyloside-inhibited
ADP/ATP carrier was made known [24] which, among other results,
aided in interpreting many structural and functional data. This was
followed by other exciting advances in understanding the func-
tional mechanism of MCs, such as identiﬁcation of the similarly lo-
cated substrate-binding site based on knowledge of substrate
speciﬁcity of carrier subfamilies, homology models and multiple
sequence alignment analysis. However, much remains to be
learned; most importantly, the precise structure of uninhibited
carriers in different conformations. It is believed that the difﬁcul-
ties encountered in crystallizing MCs under the above conditions
will be overcome in the future by improving the quality of proteins
to be investigated.
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